NCT07625150 FDG PET/MRI Imaging of Patellofemoral Joint Osteoarthritis
| NCT ID | NCT07625150 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Francisco |
| Condition | Patellofemoral Osteoarthritis |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-02-19 |
| Primary Completion | 2028-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2025-02-19 with a primary completion date of 2028-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This project aims to develop an \[18F\] fluorodeoxyglucose (FDG) positron emission tomography (PET) / magnetic resonance imaging (MRI) method to locate the painful inflammation in PFJ OA associated with joint loading. \[18F\] FDG PET/MRI is an emerging pain imaging approach with enhanced sensitivity to painful hypermetabolic inflammation through evaluation of intracellular glucose utilization rate via (\[18F\]FDG PET) and fine anatomy details (MRI). The investigative group has shown its promise in revealing previously unidentified or unspecified pain generators in various musculoskeletal pain conditions. The investigators have also demonstrated the feasibility of visualizing the structural changes between unloaded and loaded knee joints with MRI, which can be easily adopted in the current PET/MRI setting. The main challenge in the proposed \[18F\]FDG PET/MRI approach is to differentiate the normal uptake of FDG for metabolic changes by weight-bearing from abnormal changes indicating eventual pain aggravation by weight-bearing and knee-flexion. The investigators have garnered the following two aims to validate the proposed method by comparing unloaded and loaded knee imaging results between PFJ OA pain patients and asymptomatic, matched controls.
Eligibility Criteria
Inclusion Criteria: * Adult with the capacity to give informed consent * Ability to perform 25 single-leg squats * No traumatic knee injuries/surgeries since last visit for the parent study (IRB #21-34763) * No investigational drugs since last visit for the parent study (IRB #21-34763) * No contraindications to MRI or PET tracer since last visit for the parent study (IRB #21-34763) * Not taking steroid injections * Not pregnant * Additional inclusion criteria for healthy volunteers: Minimal pain (VAS=0-1) during a series of 25 single-leg squats on one or both legs Exclusion Criteria: * Inability to consent for themselves * Inability to perform 25 single-leg squats with the study leg * New traumatic knee injuries/surgeries since last visit for the parent study (IRB #21-34763) * Taking investigational drugs since last visit for the parent study (IRB #21-34763) * New contraindications to MRI or PET tracer since last visit for the parent study (IRB #21-34763) * Taking steroid injections * Pregnant * Diabetic * Additional exclusion criteria for healthy volunteers: VAS of 2 or greater during a series of 25 single-leg squats on both legs
Contact & Investigator
Richard Souza, PhD, PT
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT07625150 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Patellofemoral Osteoarthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07625150 currently recruiting?
Yes, NCT07625150 is actively recruiting participants. Contact the research team at eric.hammond@ucsf.edu for enrollment information.
Where is the NCT07625150 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT07625150 clinical trial?
NCT07625150 is sponsored by University of California, San Francisco. The principal investigator is Richard Souza, PhD, PT at University of California, San Francisco. The trial plans to enroll 50 participants.